Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA “Reminds” Doctors To Talk About Drug Benefits

Executive Summary

Proposed pilot program would look for the best patient counseling practices, but can FDA remind providers to discuss a drug’s benefits without actually specifying them?

You may also be interested in...



REMS Enhancements Could Include Provider Education Credits

FDA draft report on REMS standardization also suggests creating a patient counseling tool template for providers.

REMS Decision, Evaluation Guidances In Process, FDA Says

One draft guidance may be released this year outlining how FDA evaluates the risk-management programs.

FDA “Consumer Updates” To Get Advisory Committee Review

Agency’s Risk Communications and Advisory Committee is holding a two-day meeting to discuss how to better target FDA communications.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS055821

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel